-
1
-
-
38649132651
-
-
GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. Lyon: IARC Press; 2001.
-
GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. Lyon: IARC Press; 2001.
-
-
-
-
2
-
-
33750315764
-
Survival of patients with stage I lung cancer detected on CT screening
-
Henschke C.I., Yankelevitz D.F., Libby D.M., Pasmantier M.W., Smith J.P., and Miettinen O.S. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 355 17 (2006) 1763-1771
-
(2006)
N Engl J Med
, vol.355
, Issue.17
, pp. 1763-1771
-
-
Henschke, C.I.1
Yankelevitz, D.F.2
Libby, D.M.3
Pasmantier, M.W.4
Smith, J.P.5
Miettinen, O.S.6
-
3
-
-
0034069620
-
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
-
Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 10 (2000) 2095-2103
-
(2000)
J Clin Oncol
, vol.18
, Issue.10
, pp. 2095-2103
-
-
Shepherd, F.A.1
Dancey, J.2
Ramlau, R.3
Mattson, K.4
Gralla, R.5
O'Rourke, M.6
-
4
-
-
0034095853
-
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group
-
Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol 18 12 (2000) 2354-2362
-
(2000)
J Clin Oncol
, vol.18
, Issue.12
, pp. 2354-2362
-
-
Fossella, F.V.1
DeVore, R.2
Kerr, R.N.3
Crawford, J.4
Natale, R.R.5
Dunphy, F.6
-
5
-
-
2442661845
-
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
-
Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 9 (2004) 1589-1597
-
(2004)
J Clin Oncol
, vol.22
, Issue.9
, pp. 1589-1597
-
-
Hanna, N.1
Shepherd, F.A.2
Fossella, F.V.3
Pereira, J.R.4
De Marinis, F.5
von Pawel, J.6
-
6
-
-
22044445517
-
Erlotinib in previously treated non-small-cell lung cancer
-
Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 2 (2005) 123-132
-
(2005)
N Engl J Med
, vol.353
, Issue.2
, pp. 123-132
-
-
Shepherd, F.A.1
Rodrigues Pereira, J.2
Ciuleanu, T.3
Tan, E.H.4
Hirsh, V.5
Thongprasert, S.6
-
7
-
-
0012381722
-
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 trial)
-
[corrected]
-
Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 trial). J Clin Oncol 21 12 (2003) 2237-2246 [corrected]
-
(2003)
J Clin Oncol
, vol.21
, Issue.12
, pp. 2237-2246
-
-
Fukuoka, M.1
Yano, S.2
Giaccone, G.3
Tamura, T.4
Nakagawa, K.5
Douillard, J.Y.6
-
8
-
-
0142055937
-
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial
-
Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 16 (2003) 2149-2158
-
(2003)
JAMA
, vol.290
, Issue.16
, pp. 2149-2158
-
-
Kris, M.G.1
Natale, R.B.2
Herbst, R.S.3
Lynch Jr., T.J.4
Prager, D.5
Belani, C.P.6
-
9
-
-
27544503230
-
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
-
Thatcher N., Chang A., Parikh P., Rodrigues P.J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 9496 (2005) 1527-1537
-
(2005)
Lancet
, vol.366
, Issue.9496
, pp. 1527-1537
-
-
Thatcher, N.1
Chang, A.2
Parikh, P.3
Rodrigues, P.J.4
Ciuleanu, T.5
von Pawel, J.6
-
10
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors
-
Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 3 (2000) 205-216
-
(2000)
J Natl Cancer Inst
, vol.92
, Issue.3
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
|